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development of non-small-cell lung cancer
JK Field'"4, EM Neville', MP Stewart', A Swift', T Lilogloul, JM Risk', H Ross', JR Gosney2 and
RJ Donnelly3
'Molecular Genetics and Oncology Group, Clinical Dental Sciences, The University ofLiverpool, L69 3BX, UK; 2Department of
Pathology, The University ofLiverpool, L69 3BX, UK, 3Cardiothoracic Centre, Thomas Drive, Liverpool, L14 3PE, UK.
Summary Allelic imbalance or loss of heterozygosity (LOH) has been widely used to assess genetic instability
in tumours, and high LOH on chromosome arms 3p, 9p and 17p has been considered to be a common event in
non-small-cell lung cancer (NSCLC). We have investigated allelic imbalance in 45 NSCLCs using 92
microsatellite markers on 38 chromosome arms. LOH of 38% was observed on 3p using nine markers, 58% on
9p using 15 markers and 38% on 17p using five markers. Fractional allele loss (FAL) has been calculated for
each tumour (FAL is the number of chromosome arms showing LOH/number of informative chromosome
arms) and a median FAL value of0.09 was obtained in the 45 NSCLCs studied. The LOH data were examined
on the basis of FAL scores: low FAL (LFAL) (0.00-0.04), medium FAL (MFAL) (0.05-0.13) and high FAL
(HFAL) (0.14-0.45) based symmetrically around the median FAL value of 0.09. Tumours with HFAL values
showed a very clear polarisation of the LOH data on chromosome arms 3p, 9p and 17p, such that 80% showed
loss on 3p, 80% on 9p and 73% on 17p. These incidences of LOH were significantly higher than would be
expected, since overall genetic instability in these HFAL tumours ranged from 14% to 45% LOH. Nine of the
14 patients in the LFAL group were found to have no LOH on 3p, 9p or 17p, but five of these had LOH at
other sites: i.e. LOH on 5p, 5q, 8p, 13q, 16q and 19q. These results indicate that LFAL patients form a new
subset of NSCLC tumours with distinct molecular-initating events, and may represent a discrete genetic
population.
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Allelic imbalance or loss of heterozygosity (LOH) has been
widely used to assess genetic instability in tumour tissues.
The technique has been used primarily to identify regions on
specific chromosomes that could contain putative tumour-
suppressor genes, but may also be used to produce a
measure of accumulated genetic damage within the genome
of each tumour. A number of such allelotype analyses have
been undertaken in lung and in head and neck cancers
(Tsuchiya et al., 1992; Sato et al., 1994; Ah-See et al., 1994;
Nawroz et al.,1994; Field et al., 1995), the largest of which
has been on squamous cell carcinoma of the head and neck
(SCCHN) and involved the use of 145 microsatellite
markers (Field et al., 1995). In this study fractional allele
loss (FAL) was calculated for all tumours for which data on
nine or more chromosomal arms were available, and the
median value was found to be 0.22 (FAL was calculated as
the number of chromosome arms showing loss of
heterozygosity/number of informative chromosome arms).
A correlation between a FAL value above the median and
positive lymph nodes at pathology was demonstrated in this
study, and also between FAL>median and poor survival.
These results are in agreement with an earlier investigation
on colonic carcinomas in which a relationship was also
shown between FAL>median value and poor survival
(Vogelstein et al., 1989). A large allelotype of non-small-
cell lung cancers (NSCLCs) using 92 markers has also been
undertaken by this group and has found a median FAL
value of 0.09 (Neville et al., 1996). Long-term follow-up for
this group of NSCLC patients is as yet unavailable, thus no
statistical association has been sought between FAL and
survival.
The presence and role of allelic imbalance on the short
arms of chromosomes 3, 9 and 17 in NSCLC has received a
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great deal of attention and it has been argued that these
events are associated with the early stages of pathogenesis of
these tumours (Sundaresan et al., 1992; Hung et al., 1995;
Gazdar et al., 1994; Kishimoto et al., 1995a,b; Thiberville et
al., 1995). In these studies, the investigators studied a small
number of dysplastic and neoplastic tissues from the same
patient in great detail by performing microdissection of the
specimens. All of the six paired dysplastic and tumour tissue
specimens investigated by Sundaresan et al. (1992) showed
allelic imbalance on 3p and, similarly, Hung et al. (1995)
found that six of the seven patients examined with paired
preneoplastic and neoplastic lesions showed loss on 3p.
Kishimoto et al. (1995b) have also reported similar findings
of LOH on 9p in the same specimens. Thiberville et al. (1995)
have investigated LOH with a number of microsatellite
markers on 3p, 5q and 9p in 13 patients, demonstrating
progressive stages of bronchial carcinoma. Their results
indicate that the corresponding genetic alterations in the
dysplastic samples are often found in the invasive carcinomas
in the same patients. These results raise the question as to
whether all NSCLCs have allelic imbalance on 3p and 9p as
their initiating events. We have addressed this question by
examining allelic imbalance at 3p, 9p and 17p in 45 NSCLC
specimens for which a FAL value has been calculated. Our
results indicate that there is likely to be more than one set of
genetic events involved in the initiation and progression of
NSCLC.
Materials and methods
Samples for inclusion in this study were obtained from
patients undergoing lung resection for bronchial tumours
presenting at the Cardiothoracic Centre of the Liverpool
NHS Trust. Details of the patients have been given
previously in Neville et al. (1995a) (Table I). After
resection, the tumours were taken fresh from the theatre,
snap frozen in liquid nitrogen and each subjected to frozen
section histological examination.Distinct genetic populations in NSCLC
JK Field et al
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A, alive and well; D, died of disease, Rec.6, recurrence after
6months; DOC, died of other causes. Squamous, squamous cell
carcinoma; adenocarcinoma, adenocarcinoma of the lung; large cell,
large cell carcinoma ofthe lung.
DNA extraction
All the tumour specimens used for LOH analysis were
microdissected to yield at least 60% tumour cells before
DNA preparation. Genomic DNA was extracted from
tumour specimens using the Nucleon II DNA extraction kit
(Scotlab) following the manufacturer's instructions. Genomic
DNA samples were stored at 4°C.
Polymerase chain reaction (PCR) and LOH analysis
Microsatellite repeat primers were obtained from Isogen (The
Netherlands). PCR reactions were performed in a 25 ,l
reaction volume and contained 100 ng of genomic DNA,
200 yM each dNTP, 5 pmol each of forward and reverse
primers, 0.2 U of Taq polymerase (Bioline) and 2.5 ,l 10 x
buffer (670 mM Tris-HCl, pH 8.5; 166 mM ammonium
sulphate; 67 mm magnesium chloride; 1.7 mg ml-' bovine
serum albumin (BSA); 100 gM fl-mercaptoethanol; 1% (w/v)
Triton X-100). The reactions were denatured for 5 min at
95°C then the DNA was amplified for 30 cycles of 95°C for
30 s and 57°C for 30 s, followed by a single extension at 72°C
for 30 s. PCR product (10 yl) was electrophoresed for 10 h
Table II Loss of heterozygosity on 3p, 9p and 17p in NSCLCs
correlates with a high FAL (HFAL) value
LFAL MFAL HFAL Total
3p 3/14 (21%) 2/16 (13%) 12/15 (80%)a 17/45 (38%)
9p 2/14 (13%) 12/16 (75%) 12/15 (80%)b 26/45 (58%)
17p 1/14 (7%) 5/16 (35%) 11/15 (73%)C 17/45 (38%)
ap=0.002, LFAL compared with HFAL. bp=0.0006, LFAL
compared with HFAL. cp =0.0004, LFAL compared with HFAL.
on a 10% non-denaturing polyacrylamide gel at 250 V and
visualised by silver staining.
Statistical analysis
Quantitative data were analysed by x2 of Fisher's exact test
where appropriate.
Results
Allelic imbalance was investigated in 45 NSCLC tumours
using 92 microsatellite markers, and LOH was observed in
38% of cases on chromosome 3p using nine markers: in 58%
of cases using 15 markers on 9p and in 38% of cases using
five markers on 17p. FAL values were calculated for all of
these tumours and found to have a median of 0.09 (range
0.00-0.45). No clinical correlations were found in these
NSCLC tumours between the tumour stage or histopathology
grading and FAL (Neville et al., 1996). As these patients have
been followed up for less than 18 months, no survival
calculations were undertaken.
The LOH data for these tumours were re-examined on the
basis of their FAL scores and the tumours subdivided into
low FAL (LFAL, 0.00-0.04), medium FAL (MFAL, 0.05-
0.13) and high FAL (HFAL, 0.14-0.45) groups. These FAL
value subgroups were based symmetrically around the
medium FAL value of 0.09. The results of this analysis
demonstrated a very clear polarisation of the LOH data on
chromosomes 3p, 9p and 17p around the HFAL values
(Table II, Figure la-c).
The amount of LOH observed on 3p in NSCLC varied
according to the three subgroups of FAL: LFAL (21%),
MFAL (13%) and HFAL (80%) (Table II and Figure la).
Futhermore when the LOH data on 3p were subdivided into
the four chromosomal regions considered to contain putative
tumour-suppressor genes (3p25-p24, 3p2l, 3pl4 and 3pl3-
p12), the largest frequency of LOH was found in the HFAL
tumours at the 3pl3-pl2 region (57%), while only one
patient (L026) was observed with LOH in this region among
the LFAL NSCLC tumours (Figure la). This level of LOH
demonstrated at 3p13 -p12 by HFAL tumours is higher than
would be expected from their individual FAL scores, which
range from 14 to 45% overall loss.
Similarly, the LOH data for 9p were subgrouped on the
bases ofFAL and it was observed that only 13% ofthe LFAL
tumours haveallelicimbalance on this armcomparedwith 80%
of the HFAL NSCLC (Table II, Figure lb). Markers in the
9p23 -p22 region were found to show 67% loss in the HFAL
subgroup, a frequency of LOH which was again much higher
than that predicted by the overall FAL values in this group.
This relationship between HFAL and a high percentage ofloss
at specific chromosomal locations was further demonstrated by
the LOH data on 17p. Here, the LFAL tumours have only 7%
allelic imbalance compared with 73% for HFAL tumours
(Table II, Figure 1c). Statistical analysis of these results
demonstrated that there are a significantly higher number of
losses on 3p, 9p and 17p in the HFAL subgroups compared
with the LFAL subgroups (Table II), even taking into
consideration their different overall genomic instability as
demonstrated by their FAL ranges.
There are 14 NSCLC patients in the LFAL subgroup (with
FAL values 0.00-0.04), ofwhich three patients have LOH on
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3p (L021, L026 and L029), two patients have LOH on 9p (L029 progression ofthese cancers. Allelic imbalance was observed at
and L044) and one patient has LOH on 17p (L005). Only one D5S107, D5S111, D8S261, D13S175, D16S303 and D19S180 in
LFAL patient has LOH on 3p and 9p (L029) and no LFAL these patients with no LOH on 3p, 9p or 17p (Table III). It is of
patients have LOH on both 3p and 9p or 9p and 17p. Thus, note that LOH at D5S107 has also been found in six other
nine of the 14 patients show no allelic imbalance on 3p, 9p or tumours in the MFAL and HFAL subgroups; D8S261 LOH
17p in our analysis, demonstrating that events other than the was found in seven MFAL and HFAL tumours; D13S175
loss of these regions must be involved in the initiation and LOH was found in eight HFAL tumours; and D19S180 was
3
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Figure I FAL values associated with LOH in non small cell lung cancer on chromosome arms (a) 3p, (b) 9p and (c) 17p.Distinct genedc populations in NSCLC
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Table III Allelic imbalance in non-small-cell lung cancers with low FAL values
Number of Number of Microsatellite
microsatellite chromosome Chromosome marker
Patient markers arms FAL showing showing Chromosomal
number examined' examined value LOH LOH location
L004 80 24 0.0
LOIO 86 28 0.0
L027 69 31 0.0
L036 69 23 0.0
L005 86 32 0.03 17 D17S520 17p13
17 TP53 l7p13
L029 91 34 0.03 3 D3S1211 3p24.2-p22
9 D9S157 9p23 -p22.1
L035 74 23 0.03 19 D19S180 19q13.4
L021 81 24 0.04 3 D3S1233 3p2l
X AR Xql 1.2-ql2
L026 79 24 0.04 3 D3S1233 3p2l
3 D3S659 3p13
14 D14S50 14ql 1.2
L032 74 24 0.04 16 D16S303 16q24.3
L034 73 27 0.04 5 D5SIl I Sp
L044 85 30 0.04 9 D9S168 9p23 -p22
9 D9S157 9p23 -p22.1
14 D14S50 14q11.2
L045 79 25 0.04 5 D5S107 5ql1.2-ql3.3
13 D13S175 13q1 -ql3
L046 69 26 0.04 8 D8S261 8p23-pll1
aTotal number ofmarkers analysed throughout the genome, including both informative and uninformative
microsatellite markers.
found in two HFAL tumours. Thus, these results imply that the
regions [5q (5q11.2-q13.3), 8p (8p23-p11), 13q (13q 1 -q13)
and 19q (19q13.4)] may play a specific role in the development
and progression of some NSCLC tumours. All but one of the
MFAL tumours had LOH at 3p, 9p or 17p, except for two
tumours (L008 and L028) with FAL values of 0.10 and 0.13
respectively, which had losses on other chromosome arms.
In Tables III and IV it may be seen that there was no
significant difference in the number of markers used in the
analysis of LFAL and HFAL tumour specimens, LFAL
(median 80, range 91-69) and HFAL (median 87, range 92-
76), thus there was no bias in the analysis of the LFAL and
HFAL subgroups.
These 45 NSCLCs were also assessed for microsatellite
instability (Field et al., unpublished results), but no association
was observed between microsatellite instability and FAL value
or LOH on the individual chromosome arms 3p, 9p or 17p. Itis
of note that one of the four LFAL tumours that had no
demonstrable LOH on any chromosomal arm gave evidence of
microsatellite instability (L010), and patient L027 was found to
have a p53 mutation (Liloglou et al. submitted).
Discussion
Allelic imbalance has been demonstrated in these NSCLC on
3p, 9p and 17p, in agreement with other studies, and
correlates with tumours showing a high FAL value: 80%
on 3p, 80% on 9p and 73% on 17p, when the FAL values
range from 0.14-0.45. However, in tumours with very low
FAL values, LOH on these three chromosome arms was
found at a low frequency, which is not an unexpected result,
since LFAL =0.0-0.04 and the probability of observing
LOH on any one arm increases with increasing FAL values.
Previous studies in a small number of NSCLC specimens
have shown an association between LOH on 3p and 9p in
preneoplastic and neoplastic NSCLC specimens, and the
authors argued that this represented one of the earliest
genetic events in this disease (Sundaresan et al., 1992; Hung
et al., 1995; Kishimoto et al., 1995b; Thiberville et al., 1995).
However our results indicate that these genetic aberrations
are only observed in NSCLC tumours that also demonstrate
high levels of LOH across the rest of the genome.
The most informative tumours in our analysis are those
tumours with the minimum amount of genetic instability (i.e.
those with a low FAL value or those with no detectable LOH
on any chromosome arm). It can be argued that not all
NSCLCs arise from histologically recognisable dysplastic
lesions and thus some tumours may never go through this
pathologically identifiable route. In the NSCLCs investigated
in this study, 9 of the 14 LFAL specimens did not have allelic
imbalance at 3p, 9p or 17p, indicating that another genetic-
initiating event must be important in these tumours. All of
the markers listed in Table III may be considered to represent
new target sites in NSCLC; however, only D5S107, D8S261
and D13S175 had greater than 20% LOH in the alleotype
study (Neville et al., 1996).
In the group of four tumours with no LOH identified in
this analysis (L004, LOIO, L027 and L036), one tumour
(LOIO) was found to have microsatellite instability at D4S194
and patient L027 was found to have a p53 mutation. In
addition, no correlation was found between FAL and
microsatellite instability (Field et al., unpublished results),
ras mutations in codon 12 (Neville et al., 1995b) or p53
mutations (Liloglou et al., submitted). These results indicate
that the initiating events involved in the development of
NSCLC do not have to involve LOH on 3p, 9p or 17p (i.e. at
the sites of a putative tumour-suppressor gene), but tumours
may arise, without showing LOH, from a mutation in a
DNA repair gene, in a known tumour-suppressor gene or by
methylation of a tumour-suppressor gene.
From the results of this study, we propose that there may
be at least two initiating mechanisms in the development of
NSCLC. It may be argued that all NSCLCs with a high FAL
value have accumulated a great deal of genomic instability,
especially in the 3p, 9p and 17p regions, wherease NSCLCs
with low FAL values have very little genetic damage as
assessed by these LOH techniques. However, as all of the
tumours investigated in this study required surgical excision
and no correlations were found between FAL and any of the
clinicopathological parameters (i.e. site, pathology and TNM
stage), only genomic instability differentiates these two
groups.
We propose that there is a subgroup of NSCLC patients
with allelic imbalance on chromosomal regions previously
associated with dysplastic lesions (3p, 9p and 17p), which isDistinct genetic populations in NSCLC
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Table IV Allelic imbalance in non-small-cell lung cancers with HFAL values
No. of No. of chromosome
Patient markers arms Microsatellite
number analysedf examined FAL Location marker(s)
L016 87 21 0.14 4q D4S194
9p ~~D9S161, D9S269, D9S162, D9S285, D9SI57,
D9S286
12p D12S70
L042 91 26 0.15 3p D3S1233
3q D3S1215
4q D4S194
6p D6S271
9q D9S180
22q IL2RB
L023 84 25 0.16 3p D3S1079, D3S659, D3S966
4q D4S392, D4S194
6 ACTBP2
9p D9S161, D9S171, D9S168, D9S162, D9S285,
D9S157, D9S156
12p DRPLA
13q D13S175
17p TP53
L018 83 28 0.18 13p D3S1293
13q D13S155
14q D14S50
17p D17S520
17q GP3A
18q D18S35
L049 85 27 0.19 3p D3S966
4q FGA, D4S392, D4S194
Sq D5S107
9p D9S171, D9S178, D9S286
13q D13S175
17p CHRNB1
L051 87 26 0.19 3p D3S659
4q D4S194
8p D8S261
9p D9S269, D9S157
9q D9S103
12p DRPLA
17p CHRNB1, TP53
L030 85 30 0.2 2q D2S104
zip HOX7
5q D5S107
8p D8S261
12p DRPLA
17p D17S520
18q DCC
L041 85 27 0.22 3p D3S1233, D3S1284
3q D3S1215
4q D4S194
8p D8S261
9p D9S199
12p D12S94
13q D13S168
L012 91 30 0.23 3q D3S1215
8p D8S261
9p D9S200, D9S161, D9S157
13q D13S168, D13S155
17p D17S578
17q D17S515
22q IL2RB
L037 89 26 0.23 3p D3S1293
4q D4S392
6p D6S271
8p D8S261
9p D9S285
13q D13S175
17p D17S122, D17S520
17q GP3A
L055 76 27 0.26 3p D3S659, D3S1079, D3S966
3q D3S1215
4q FGA
9p D9S285, D9S157, D9S156, D9S199, D9S178
9q D9S103
13q D13S168
16p HBAP1
19q D19S180
ContinuedDistinct genetic populations in NSCLC x
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Table IV continued
No. of No. of chromosome
Patient markers arms Microsatellite
number analysed' examined FAL Location marker(s)
3p D3S659, D3S1079, D3S1217, D3S966, D3S1293
3q D3S1215
4q FGA
5q D5S107
9p D9S168
13q D13S155, D13S175, D13S168
14q D14S50
17p TP53
L052 87 28 0.29 3p D3S1079, D3S659, D3S1235
4q D4S194
5q D5S107
9p IFNA, D9S168, D9S157
9q D9S177, ASS
12p D12S70
13q D13S115, D13S175
17p CHRNB1, TP53, D17S578
21q D21S156
L050 87 30 0.3 3p D3S1211
9p D9S200, IFNA, D9S162, D9S168, D9S157,
D9S178
9q D9S67, ASS
13q D13S155, D13S175
14q D14S50
17p D17S520
18q MBP
19p D19S20
19q D19S180
21q D21S156
L003 92 29 0.45 lp DIS167
lq DlS104
2q ILIA
3p D3S659
3q D3S1269
8q MYC
9p D9S171, D9S168, D9S157, D9S178
9q ASS
13q D13S168
17p D17S122, D17S520, TP53
17q TCF2
18p D18S52
18q MBP
aTotal number ofmarkers analysed throughout the genome, including both informative and uninformative microsatellite markers.
associated with high levels of allelic imbalance across the
whole genome (HFAL tumours). In our analysis, the most
important group, as previously discussed, is the LFAL
subgroup, which may not go through the histologically
recognisable dysplastic phase of neoplastic development and
thus will have been missed by previous investigators who
have concentrated on patients demonstrating these two
histological stages of the disease. These LFAL tumours do
not commonly have allelic imbalance on 3p, 9p or 17p and it
may be argued that they represent a new subset of patients
with different molecular-initiating events in NSCLC and thus
may be considered to represent a distinct genetic population
in NSCLC. In subgroup I, the inactivated and/or mutated
genes on 3p, 9p and 17p are observed concurrently with gross
genetic instability as evaluated by FAL value, whereas the
genes involved in subgroup II (LFAL) do not appear to be
associated with such gross instability and probably represent
an alternative pathway(s) in the development of NSCLC.
Currently, we are involved in elucidating the genetic
alterations in the LFAL subgroup.
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